Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial.
Lower-dose radiation combined with immunotherapy provided lasting disease control in localized lymphomas, suggesting a gentler approach may work.
While involved-site radiotherapy (ISRT) is the standard first-line treatment in localized non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma, the cumulative risk of distant relapse poses a persistent clinical . Overall, the combined immunoradiotherapy regimen demonstrated durable disease control in localized non-gastric MALT lymphoma, with potential synergistic benefit from NK cell-mediated immune activation.
What the study was
- Study design
- Phase 2 clinical trial
- Population
- Cancer/disease patients
- Sample size
- 60
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Leukemia
Why it surfaced
Matched topic(s): Hematologic malignancies. Study design: Phase 2 clinical trial. Published in high-impact journal. Score 7/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.